It is indicated for the treatment of schizophrenia as well as for the treatment of acute manic episodes associated with bipolar I disorder. Ever since our establishment in the 2004, we are engaged in offering Quetiapine Hemifumarate. This compound exhibits antagonist activity at dopamine and serotonin receptors. Specifically the D1 and D2 dopamine, the alpha 1 adrenoreceptor and alpha 2 adrenoreceptor, and 5-HT1A and 5-HT2 serotonin receptor subtypes are antagonized. Quetiapine Hemifumarate also has an antagonistic effect on the histamine H1 receptor. It is used for the treatment of schizophrenia and related psychotic disorders.